What is Adela?
Adela is a specialized biotechnology firm dedicated to transforming cancer care through innovative blood-based detection and monitoring solutions. The company utilizes sophisticated DNA methylation technology to identify cancer signatures, providing clinicians with actionable insights for early detection, treatment response assessment, and recurrence tracking. By shifting the paradigm from invasive tissue biopsies to streamlined liquid biopsies, Adela aims to improve patient outcomes and reduce the burden of diagnostic procedures in oncology. Its market position is bolstered by a robust portfolio of intellectual property and a clear focus on high-impact clinical applications within the global diagnostics landscape.
How much funding has Adela raised?
Adela has raised a total of $53M across 2 funding rounds:
Other Financing Round
$48M
Debt
$5M
Other Financing Round (2023): $48M with participation from Decheng Capital, Deerfield, F-Prime Capital Partners, OrbiMed, and RA Capital Management
Debt (2026): $5M, investors not publicly disclosed
Key Investors in Adela
Decheng Capital
Decheng Capital is a global investment firm specializing in providing capital and strategic support to early-stage life science companies and growth-stage healthcare ventures.
Deerfield
Deerfield Management is an investment firm focused on advancing healthcare through investment, intelligence, and philanthropy, supporting companies across the entire healthcare ecosystem.
OrbiMed
OrbiMed Advisors LLC is a specialized investment firm with deep expertise in biopharmaceuticals, medical devices, and diagnostics, managing capital across the entire healthcare innovation cycle.
What's next for Adela?
With this recent capital injection, Adela is well-positioned to accelerate its clinical development programs and expand the utility of its liquid biopsy platform. The company's strategic roadmap likely involves scaling its diagnostic capabilities to support broader clinical adoption and deepening its research into diverse cancer types. As the healthcare industry increasingly prioritizes early intervention and personalized treatment protocols, Adela's ability to provide precise, longitudinal data will be instrumental in securing its role as a key partner for healthcare providers and pharmaceutical developers alike. The firm remains focused on translating complex genomic data into clinical value, ensuring that its technology meets the rigorous demands of both regulatory bodies and the medical community.
See full Adela company page
